Department of Ophthalmology, National Defense Medical College, Tokorozawa, Japan.
Department of Ophthalmology, Hyogo College of Medicine, Nishinomiya, Japan.
PLoS One. 2021 Oct 8;16(10):e0258415. doi: 10.1371/journal.pone.0258415. eCollection 2021.
Intravitreal anti-VEGF injection (IVI) is administered before vitrectomy to assist management of proliferative diabetic retinopathy (PDR)-related complications. In the clinical setting, retinal surgeons determine the use of preoperative IVI based on individual criteria. In this study, we investigated factors related to the potential bias of retinal surgeons in using IVI prior to vitrectomy for PDR-related complications, and evaluated the real-world outcomes of surgeon-determined preoperative IVI.
Medical records of 409 eyes of 409 patients who underwent 25-gauge vitrectomy for PDR complications at seven Japanese centers (22 surgeons) were retrospectively reviewed. Ocular factors, demographic and general clinical factors, surgical procedures, and postoperative complications were compared between IVI group (patients who received preoperative IVI; 87 eyes, 21.3%) and non-IVI group (patients who did not receive preoperative IVI; 322 eyes, 78.7%). In addition, baseline HbA1c in IVI group and non-IVI group was compared between eyes with and without postoperative complications.
At baseline, IVI group was younger (P<0.001), had shorter duration of diabetes treatment (P = 0.045), and higher frequencies of neovascular glaucoma [NVG] (P<0.001) and tractional retinal detachment [TRD] (P<0.001) compared to non-IVI group. Although IVI group had higher frequencies of intraoperative retinal break and tamponade procedure, there were no significant differences in postoperative complications and additional treatments between two groups. Baseline HbA1c levels were also not correlated with postoperative complications of VH, NVG, and RD both in IVI group and non-IVI group. Logistic regression analysis identified age (P<0.001, odds ratio [OR] 0.95), presence of NVG (P<0.001, OR 20.2), and presence of TRD (P = 0.0014, OR 2.44) as preoperative factors in favor of IVI.
In this multicenter real-world clinical study, younger age and presence of NVG and TRD were identified as potential biases in using IVI before vitrectomy for PDR complications. Eyes that received preoperative IVI had more intraoperative retinal breaks requiring tamponade than eyes not receiving IVI, but postoperative outcome was not different between the two groups.
玻璃体内抗血管内皮生长因子注射(IVI)在玻璃体切割术前给予,以协助治疗增生性糖尿病视网膜病变(PDR)相关并发症。在临床环境中,视网膜外科医生根据个人标准来决定是否在术前使用 IVI。在这项研究中,我们研究了与视网膜外科医生在玻璃体切割术前使用 IVI 以治疗 PDR 相关并发症时潜在偏见相关的因素,并评估了外科医生决定术前 IVI 的真实世界结果。
回顾性分析了在七个日本中心(22 名外科医生)接受 25 号玻璃体切割术治疗 PDR 并发症的 409 例患者(409 只眼)的病历。比较了 IVI 组(接受术前 IVI 的患者;87 只眼,21.3%)和非-IVI 组(未接受术前 IVI 的患者;322 只眼,78.7%)之间的眼部因素、人口统计学和一般临床因素、手术过程和术后并发症。此外,还比较了 IVI 组中伴有和不伴有术后并发症的患者的基线 HbA1c。
在基线时,IVI 组年龄更小(P<0.001),糖尿病治疗时间更短(P=0.045),新生血管性青光眼[NVG](P<0.001)和牵引性视网膜脱离[TRD](P<0.001)的发生率更高。尽管 IVI 组术中视网膜裂孔和填塞术的发生率较高,但两组间术后并发症和附加治疗无显著差异。IVI 组和非-IVI 组中,基线 HbA1c 水平也与 VH、NVG 和 RD 的术后并发症均无相关性。Logistic 回归分析确定年龄(P<0.001,优势比[OR]0.95)、NVG 的存在(P<0.001,OR 20.2)和 TRD 的存在(P=0.0014,OR 2.44)为术前有利于 IVI 的因素。
在这项多中心真实世界临床研究中,年轻、存在 NVG 和 TRD 被确定为在玻璃体切割术前使用 IVI 治疗 PDR 并发症时的潜在偏见。接受术前 IVI 的眼比未接受 IVI 的眼在术中需要更多的视网膜填塞,但两组的术后结果无差异。